IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.48 HKD | +3.58% |
|
-0.69% | -51.57% |
| 06-03 | ImmuneOnco Biopharmaceuticals Gets China's Phase 3 Trial Approval for Leukemia Drug | MT |
| 05-30 | ImmuneOnco Completes Filing with China Regulator for Conversion of H Shares | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- One of the major weak points of the company is its financial situation.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -51.57% | 694M | - | ||
| +15.19% | 121B | B+ | ||
| +19.91% | 114B | B+ | ||
| +8.24% | 23.61B | B | ||
| -19.80% | 20.43B | B+ | ||
| -16.19% | 16.55B | A- | ||
| -13.45% | 16.45B | B | ||
| -44.35% | 15.59B | A- | ||
| +66.67% | 15.19B | C+ | ||
| +2.13% | 13.54B | C+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 1541 Stock
- Ratings ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
